Identification Generic Name (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol DrugBank Accession Number DB08321 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol (DB08321) ×  Close Weight Average: 287.3951  Monoisotopic: 287.209658421  Chemical Formula C 15 H 29 NO 4 Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Alpha-mannosidase 2 Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Chemical Taxonomy Provided by  Classyfire Description This compound belongs to the class of organic compounds known as cyclitols and derivatives. These are compounds containing a cycloalkane moiety with one hydroxyl group on each of three or more ring atoms. These of also include derivatives where the hydrogen atom of one or more of the hydroxyl groups is replaced with another atom. Kingdom Organic compounds Super Class Organic oxygen compounds Class Organooxygen compounds Sub Class Alcohols and polyols Direct Parent Cyclitols and derivatives Alternative Parents Secondary alcohols  /  Polyols  /  Dialkylamines  /  Primary alcohols  /  Organopnictogen compounds  /  Hydrocarbon derivatives Substituents Aliphatic homomonocyclic compound  /  Amine  /  Cyclitol or derivatives  /  Hydrocarbon derivative  /  Organic nitrogen compound  /  Organonitrogen compound  /  Organopnictogen compound  /  Polyol  /  Primary alcohol  /  Secondary alcohol Molecular Framework Aliphatic homomonocyclic compounds External Descriptors Not Available Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key UPZUHYMBTUUPML-KBXIAJHMSA-N InChI InChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13-,14+,15+/m1/s1 IUPAC Name (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol SMILES [H][C@@]1(O)C(CO)=C[C@@]([H])(NCCCCCCCC)[C@]([H])(O)[C@@]1([H])O References General References Not Available External Links PubChem Compound 9817381 PubChem Substance 99444792 ChemSpider 7993131 BindingDB 50358322 ChEMBL CHEMBL1234952 ZINC ZINC000014175217 PDBe Ligand OEV PDB Entries 3d50 Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 11.3 mg/mL ALOGPS logP 0.95 ALOGPS logP 0.4 Chemaxon logS -1.4 ALOGPS pKa (Strongest Acidic) 12.83 Chemaxon pKa (Strongest Basic) 8.47 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 92.95 Å 2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 78.94 m 3 ·mol -1 Chemaxon Polarizability 33.59 Å 3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 0.9482 Blood Brain Barrier - 0.9787 Caco-2 permeable - 0.6232 P-glycoprotein substrate Substrate 0.7566 P-glycoprotein inhibitor I Non-inhibitor 0.8102 P-glycoprotein inhibitor II Non-inhibitor 0.6793 Renal organic cation transporter Non-inhibitor 0.825 CYP450 2C9 substrate Non-substrate 0.81 CYP450 2D6 substrate Non-substrate 0.6983 CYP450 3A4 substrate Non-substrate 0.578 CYP450 1A2 substrate Non-inhibitor 0.7367 CYP450 2C9 inhibitor Non-inhibitor 0.8951 CYP450 2D6 inhibitor Non-inhibitor 0.744 CYP450 2C19 inhibitor Non-inhibitor 0.898 CYP450 3A4 inhibitor Non-inhibitor 0.9826 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9125 Ames test Non AMES toxic 0.8035 Carcinogenicity Non-carcinogens 0.9477 Biodegradation Ready biodegradable 0.6596 Rat acute toxicity 2.0258 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6589 hERG inhibition (predictor II) Non-inhibitor 0.748    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  Alpha-mannosidase 2 Kind Protein Organism Humans Pharmacological action Unknown General Function Zinc ion binding Specific Function Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway. Gene Name MAN2A1 Uniprot ID Q16706 Uniprot Name Alpha-mannosidase 2 Molecular Weight 131139.485 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:30 / Updated at June 12, 2020 16:52 